(IDIX) to Raise $106.7 Million Through Registered Direct Offering
CAMBRIDGE, Mass., Jan. 28, 2014 — Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has entered into a definitive agreement with certain entities managed by The Baupost Group, L.L.C. (Baupost) for the sale of 16,420,241 shares of its common stock. Baupost has agreed to purchase the shares of common stock at a price of $6.50 per share, resulting in net proceeds to Idenix, after deducting estimated offering expenses, of approximately $106.7 million.
Baupost, which currently owns approximately 27% of the Company’s outstanding common stock, will beneficially own approximately 35% of the Company’s outstanding common stock upon completion of the offering. The sale and issuance of the shares is expected to close on or about January 31, 2014, subject to customary closing conditions. The proceeds of this offering will be used for general corporate purposes, including clinical trial costs and ongoing and future patent litigation expenses. The Company believes that its current cash and cash equivalents balance and the net proceeds from this offering will be sufficient to satisfy cash needs into at least the second half of 2015.
Pursuant to a letter of agreement between the parties, the Company has agreed that Baupost, for so as long as it holds at least 25% of the Company’s outstanding common stock, is entitled to observer rights with respect to meetings of the board of directors of the Company.
The securities described above are being offered directly to the purchasers by Idenix pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (the “SEC”). This press release is not an offer to sell any of the securities described herein, and this press release is not an offer to buy these securities in any state where the offer or sale is not permitted. Copies of the prospectus supplement and accompanying base prospectus relating to this offering may be obtained by visiting EDGAR on the SEC’s website at www.sec.gov.
ABOUT IDENIX
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix’s current focus is on the treatment of patients with hepatitis C infection. For further information about Idenix, please refer to www.idenix.com.
FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements, other than statements of historical fact, regarding, without limitation, the completion, timing and size of the Company’s proposed offering and the use of proceeds therefrom. In some cases, words such as “will,” “expect” or other comparable words identify forward-looking statements. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various important factors, including without limitation risks and uncertainties relating to the Company’s business and financial condition, general market conditions and the satisfaction of customary closing conditions associated with the proposed offering. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not the Company will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed offering and the impact of general economic, industry or political conditions in the United States or internationally. Risks and uncertainties that the Company faces are described in greater detail under the heading ” Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2012 and the quarterly report on Form 10-Q for the quarter ended September 30, 2013, each as filed with the SEC and in any subsequent periodic or current report that the Company files with the SEC. As a result of the risks and uncertainties, the results or events indicated by any forward-looking statement may not occur. The Company cautions you not to place undue reliance on any forward-looking statement.
All forward-looking statements reflect the Company’s views only as of the date of this release and should not be relied upon as reflecting the Company’s views, expectations or beliefs at any date subsequent to the date of this release. While the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if the Company’s views, expectations or beliefs change.
CONTACT: Idenix Pharmaceuticals Contact: Teri Dahlman (617) 995-9807
TraderPower Featured Companies
- Astrotech Corp. (NASDAQ: ASTC)
- Cepton Inc. (NASDAQ: CPTN)
- Clene Inc. (NASDAQ: CLNN)
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
- Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)
- Freight Technologies Inc. (NASDAQ: FRGT)
- InMed Pharmaceuticals Inc. (NASDAQ: INM)
- Lexaria Bioscience Corp. (NASDAQ: LEXX)
- Mullen Automotive Inc. (NASDAQ: MULN)
- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)
Top Small Cap Market News
- $NTRB InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Enters Exclusive Supplier Agreement with Major Sports Brand Licensee
- $FNGR China Reportedly Asks Telcos to Halt Using Foreign-Sourced Chips
- $CNSP InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024
- $DLMI InvestorNewsBreaks – Diamond Lake Minerals Inc. (DLMI), BOXABL Partnership Highlighted in Proactive Article
- $SUIC InvestorNewsBreaks – SUIC Worldwide Holdings Ltd (SUIC) Featured in Bell2Bell Podcast
- $GTVH InvestorNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Making Significant Strides to Create Premier Entertainment Destination
- $CIPI Distributed Energy Solutions Provider Correlate Energy Corp. (CIPI) Making Significant Alternative Power Transition an Affordable Reality
- $PXMD InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Responds to Emergency Request for IV Suramin, Commits to Provide Immediate Access to PAX-101
- $ZDPY InvestorNewsBreaks – Zoned Properties Inc. (ZDPY) Announces $1M Stock Repurchase Program
- $SPCB SuperCom Ltd. (NASDAQ: SPCB) Electronic Monitoring Technology Addresses Important Concerns in Dealing with Youthful Offenders
- $FRGT InvestorNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Announces Strong Revenue Growth for Q1 2024
- $EAWD InvestorNewsBreaks – Energy and Water Development Corp. (EAWD) Makes Key Move to Strengthen Compliance and Legal Operations
Recent Posts
- $EAWD InvestorNewsBreaks – Energy and Water Development Corp. (EAWD) Makes Key Move to Strengthen Compliance and Legal Operations
- $FRGT InvestorNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Announces Strong Revenue Growth for Q1 2024
- $SPCB SuperCom Ltd. (NASDAQ: SPCB) Electronic Monitoring Technology Addresses Important Concerns in Dealing with Youthful Offenders
- $ZDPY InvestorNewsBreaks – Zoned Properties Inc. (ZDPY) Announces $1M Stock Repurchase Program
- $PXMD InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Responds to Emergency Request for IV Suramin, Commits to Provide Immediate Access to PAX-101
- $CIPI Distributed Energy Solutions Provider Correlate Energy Corp. (CIPI) Making Significant Alternative Power Transition an Affordable Reality
- $GTVH InvestorNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Making Significant Strides to Create Premier Entertainment Destination
- $SUIC InvestorNewsBreaks – SUIC Worldwide Holdings Ltd (SUIC) Featured in Bell2Bell Podcast
Recent Comments
Archives
- April 2024
- January 2023
- June 2022
- December 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009